Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab With or Without Chemotherapy for Resectable Pleural Mesothelioma
NCT05932199Phase 2Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Jul 2024
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in malignant pleural mesothelioma (MPM), sponsored by Baylor College of Medicine. Started Jul 2024; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05932199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932199.